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Abstract
It has been well-documented that leukotrienes (LTs)
are released in allergic lung inflammation and that
they participate in the physiopathology of asthma. A
role for LTs in innate immunity has recently emerged:
Cys-LTs were shown to enhance FcγR-mediated
phagocytosis by alveolar macrophages (AMs). Thus,
using a rat model of asthma, we evaluated FcγR-
mediated phagocytosis and killing of Klebsiella
pneumoniae by AMs. The effect of treatment with a
cys-LT antagonist (montelukast) on macrophage
function was also investigated. Male Wistar rats were
immunized twice with OVA/alumen intraperitoneally
and challenged with OVA aerosol. After 24 h, the
animals were killed, and the AMs were obtained by
bronchoalveolar lavage. Macrophages were cultured
with IgG-opsonized red blood cells (50:1) or IgG-
opsonized K. pneumoniae (30:1), and phagocytosis
or killing was evaluated. Leukotriene C4 and nitric
oxide were quantified by the EIA and Griess methods,
respectively. The results showed that AMs from
sensitized and challenged rats presented a markedly
increased phagocytic capacity via FcγR (10X
compared to controls) and enhanced killing of K.
pneumoniae (4X higher than controls). The increased
phagocytosis was inhibited 15X and killing 3X by
treatment of the rats with montelukast, as compared
to the non-treated group. cys-LT addition increased
phagocytosis in control AMs but had no effect on
macrophages from allergic lungs. Montelukast
reduced nitric oxide (39%) and LTC4 (73%). These
results suggest that LTs produced during allergic lung
inflammation potentiate the capacity of AMs to
phagocytose and kill K. pneumonia via FcγR.
Introduction
Macrophages are the first line of defense and exhibit
a variety of activities, including induction of inflammation,
engulfment of microorganisms and dead cells, Ag
presentation, and regulation of extracellular components.
Alveolar macrophages (AMs) also produce and secrete
inflammatory cytokines, chemokines and lipid mediators
such as leukotrienes (LTs), and therefore, they play an
important role in innate immunity [1, 2]. Leukotrienes are
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produced in response to a variety of infectious agents
and enhance diverse leukocyte functions, including
adherence, phagocytosis [3], secretion of reactive oxygen
intermediates [4] and chemokine synthesis [5]. These
effects of leukotrienes are so important that in animal
models of infection, the pharmacological inhibition of
leukotriene synthesis impairs the clearance of
microorganisms and increases susceptibility to myriad
different infections [3, 6-8].
Arachidonic acid (AA), a normal component of cell
membrane phospholipids, is a substrate for prostaglandin
endoperoxide (PGH) syntases-1 and -2, also known as
cyclooxygenase (COX)-1 and -2, lipoxygenase (5-, 12-,
or 15) (LO) or cytochrome p450 enzymes. Leukotrienes
are produced in a multi-step enzyme pathway called the
5-lipoxygenase (5-LO) pathway, which is active in
leukocytes such as neutrophils, eosinophils, mast cells and
monocytes [9]. LTs exert their biological effects by
activating specific receptors belonging to the superfamily
of G protein-coupled receptors, including both LTB4 and
the cysteinyl LTs (cys-LTs) C4, D4, and E4. Two receptors
for LTB4 have been identified: BLT1 and BLT2. BLT1 is
a high-affinity receptor that is specific for LTB4, which is
expressed primarily in leukocytes and mediates
chemotaxis; BLT2 is a pharmacologically distinct receptor
that is ubiquitously expressed, displays a low affinity for
LTB4 and binds to other eicosanoids. Receptors that are
activated in response to Cys-LTs were cloned in 1999
and termed CysLT1 and CysLT2. CysLT1 recombinant
receptor is activated by all of the native ligands with the
following order of potency: LTD4 > LTC4 > LTE4. In
contrast, the agonist rank order potency for the CysLT2
receptor is LTD4 = LTC4, with LTE4 demonstrating less
potency [10].
Leukotrienes are produced during allergic lung
inflammation and are responsible for several inflammatory
events. Their role in experimental models of allergic
asthma has been well documented [11, 12]. Several
studies have demonstrated that LTs are also relevant in
human asthma, and the use of cys-LT antagonists has
demonstrated beneficial effects. Cys-LTs are released
from inflammatory cells that participate in the pathogenesis
of allergic rhinitis [13], are elevated in patients with
perennial allergic rhinitis [14], and are released following
allergen exposure [15]. The CysLT1 receptor is expressed
in nasal inflammatory cells and nasal mucosal glands [16],
and CysLT administration reproduces the symptoms of
allergic rhinitis. Moreover, CysLT1 receptor antagonists
reduce the symptoms and signs of allergic rhinitis, reducing
nasal allergic inflammation [13].
The phagocytosis of opsonized particles is triggered
by the interaction of opsonins with specific receptors on
the phagocyte surface. One of the most proeminent and
well-studied phagocytic receptors is the Fcγ receptor
(FcγR), which binds to the Fc portion of immunoglobulins
(Ig) that coat the target [17]. LTB4 and cys-LTs (LTD4)
have been shown to enhance FcγR-mediated phagocytosis
by AMs [2].
Considering that cys-LTs are produced in asthmatic
lungs and enhance the phagocytic and microbicidal effects
of AMs, we investigated the phagocytic and microbicidal
activities of macrophages from rat lungs undergoing
allergic lung inflammation.
Materials and Methods
Animals
Eight to twelve-week-old Male Wistar rats (250-300 g)
from our own colony were housed in a 22 ± 1°C environment at
60% humidity and were maintained on a 12-h light–dark cycle
with food and water provided ad libitum. All procedures used
in this study were approved and performed in accordance with
guidelines established by the Brazilian College of Animal
Experimentation (COBEA) and were approved by the Biomedical
Sciences Institute/USP–Ethical Committee for Animal Research
(CEEA).
Immunization protocol
Rats were sensitized on days 0 and 7 by an intraperitoneal
injection of a mixture containing 50 mg of ovalbumin and 1 mg
of Al(OH)3 in saline (total volume of 0.7 ml). At day 14 after the
first immunization, the animal were challenged by exposure to
an aerosol of ovalbumin (grade III, Sigma) generated with an
ultrasonic nebulizer (ICEL US-800, SP, Brazil) that delivers
particles of 0.5–10 µm in diameter at approximately 0.75 ml/min
for 20 min. The concentration of ovalbumin in the nebulizer
was 2.5% (w/v).
The control group consisted of animals that were
immunized as described and challenged with saline solution.
The experimental groups of animals were treated 30 min before
each challenge with effective doses of a cysteinyl-leukotriene
receptor antagonist (montelukast, 5 mg/kg i.p.).
Bronchoalveolar lavage
Rats were killed with an overdose of anesthesia 24 h after
exposure to aerosol challenge. A tracheal cannula was inserted
via a midcervical incision, and the airways were lavaged five
times with 10 ml of phosphate-buffered saline (PBS, pH 7.4 at
4°C).
Total and differential cell counts
The bronchoalveolar lavage fluid (BALF) was centrifuged
at 170 g for 10 min at 4ºC, the supernatant was removed, and
the cell pellet was resuspended in 0.5 ml of PBS. One volume of
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a solution containing 0.5% crystal violet dissolved in 30% acetic
acid was added to nine volumes of the cell suspension. The
total number of cells was determined by counting using a
hemocytometer. Differential cell counts were performed after
cytocentrifugation and staining with hematoxylin and eosin
(Hema 3).
Cell isolation and culture
Resident AMs from rats were obtained via ex vivo lung
lavage as previously described [2] and resuspended in RPMI-
1640 (Gibco-Invitrogen, Carlsbad, CA) to a final concentration
of 2x105 cells/mL. The cells were allowed to adhere to culture
plates for 1 hour (37°C, 5% CO2) followed by one wash with
warm RPMI-1640. More than 99% of the adherent cells were
identified as AMs according to a modified Wright-Giemsa stain.
Cells were cultured overnight in RPMI-1640 supplemented with
2% fetal bovine serum (FBS) and then washed twice with warm
medium to remove non-adherent cells.
Phagocytosis of red blood cells opsonized with IgG and
evaluation of the phagocytic index
Red blood cells (Bioboavista Laboratories, Brazil) were
opsonized with a subagglutinating concentration of IgG rabbit
anti-sheep erythrocyte antibody (IgG-RBCs) (Cappel Organon
Teknika, Durham, NC) as previously described [18].
The phagocytosis of lamb red blood cells by rat AMs
was evaluated according a method previously described by
Aronoff et al. [19]. Briefly, 2 x 105 cells were added to each well
of a 24-well culture plate and allowed to adhere for 1 hour
(37°C, 5% CO2). The cell monolayer was washed to remove
non-adherent cells and then cultured for 18 hours in RPMI
containing 2% fetal bovine serum (HyClone, Logan, UT-USA),
according to Serezani et al. [2].
The alveolar macrophages were washed with PBS at 37oC
and incubated with or without LTC4 (100 nM) (Biomol Inc.,
Palo Alto, CA-USA) for 10 minutes. Following the incubation,
the supernatant was removed, and opsonized blood cells or
not opsonized (internalization control) were added to the AMs
at a concentration ratio of 50:1. The samples were incubated
for 90 min at 37oC and 5% CO2 in PBS. After phagocytosis, the
cells were washed three times with PBS and stained with
hematoxylin and eosin. The phagocytic index (PI), which was
derived by multiplying the percentage of positive macrophages
(AMs containing at least one ingested target) by the mean
number of phagocytosed targets per positive macrophage, was
determined by optical microscopy (x1000).
Bacterial killing assay
Klebsiella pneumoniae 43816, serotype 2 was obtained
from the American Type Culture Collection (ATCC, Rockville,
MD). Bacterial stocks were thawed, inoculated into broth, and
grown to log phase. The internalization and intracellular killing
of K. pneumoniae was monitored using a modification of the
assay described by Bidani et al. [20]. Briefly, 2x105 AMs were
suspended in RPMI and infected with K. pneumoniae at a
concentration ratio of 30:1 bacteria per cell at 37ºC for 1 h. The
cell suspensions were centrifuged (300 xg, 10 min, 4ºC), and
then the supernatants were collected, and the cells were washed
twice in PBS and lysed. Quantitative bacterial cultures were
performed for the supernatants and cell lysates to determine
the colony-forming units (CFUs) in the extracellular and
intracellular cell environments. CFUs were determined by serial
dilution on agar plates. K. pneumoniae was grown in BBL brain
heart infusion broth and nutrient agar (DIFCO; Becton
Dickinson) and incubated at 37ºC for 18–24 h.
Measurement of nitric oxide
To evaluate nitric oxide (NO) production, the nitrite
concentrations in the supernatants of the AM cultures were
measured using the standard Griess reaction [21]. Briefly, 50 μl
of supernatant culture medium was added to 50 μl of Griess
reagent [equal volumes of 1% (w/v) sulfanilamide in 2.5% (v/v)
phosphoric acid and 0.1% (w/v) naphthylenediamine-HCl] and
incubated at room temperature for 10 min. The absorbance at
540 nm was then measured in a microplate reader MultiskanEX,
and the nitrite concentration was calculated based on a standard
curve of sodium nitrite. All assays were performed in triplicate.
Extraction and quantification of leukotrienes
The octadecylsilyl silica column (Sep-Pak C18 column)
was pre-washed with 10 ml of ethanol and 10 ml of water, and
the supernatants from homogenized and acidified lung tissues
(pH 3.4–3.6 with HCl 1 N) were allowed to pass slowly through
the column. The column was then washed with 10 ml water and
1 ml ethanol (35%), and the eicosanoids were eluted from the
column with 2 ml absolute ethanol. The samples were dried
under a stream of nitrogen. LTC4 and LTD4 concentrations were
determined using EIA kits (Cayman Chemical Co., MI, USA)
according to the method reported by Pradelles et al. [22]. Briefly,
dilutions of the supernatants were incubated with the
conjugated eicosanoid–acetylcholinesterase complex and with
specific antiserum in 96-well plates precoated with anti-rabbit
immunoglobulin G antibodies. After an overnight incubation
at 4ºC, the plates were washed, and the enzyme substrate
(Ellman’s reagent) was added for 60–120 min at 25ºC. The optical
density of the samples was determined at 412 nm using a
microplate reader, and the concentration of eicosanoids was
calculated based on a standard curve.
Statistical analysis
Data are expressed as the means ± SEM. Statistical
analyses were performed using the GraphPad software (San
Diego, CA, USA) and compared by analysis of variance
(ANOVA) followed by the Bonferroni test or the unpaired
Student t test where appropriate. A p value less than 0.05 was
considered statistically significant. All of the experiments were
performed at least three independent times.
Results
Effect of montelukast on lung cell infiltration
Rats immunized with ovalbumin were submitted to
ovalbumin aerosol challenge, and bronchoalveolar lavage
was performed 24 h after the aerosol challenge. The
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control group consisted of immunized and saline
challenged rats.
Whereas the numbers of eosinophils and neutrophils
detected in the BALF of the control group were very
low (less than 1 cell/ml), significant increases in total cells
(287.5 ± 21.8 to 778 ± 131.2 cells x104/ml), neutrophils
(0.5 ± 0.2 to 265.2 ± 81.5 cells x104/ml) and eosinophils
(0.5 ± 0.2 to 107.8 ± 25 cells x104/ml) were observed in
the immunized and antigen-challenged rats (Fig. 1A, B
and C). The groups of immunized rats received
intraperitoneal injections of selected effective doses of
antagonists of cysteinyl-leukotrienes (Montelukast, 5 mg/
kg) 30 min before aerosol antigen challenges. Figure 1A,
B and C shows that all treatments significantly decreased
the numbers of total cells (50%), neutrophils (92%) and
eosinophils (88%) in the bronchoalveolar lavage fluid of
rats following treatment with the cysteinyl-leukotriene
receptor antagonist.
Effect of montelukast on leukotriene production
in lung tissue
The lung tissues were homogenized and centrifuged,
and the LTB4 and LTC4/D4 concentrations were
determined using EIA kits. The animals that were
immunized and sensitized demonstrated increased levels
of LTB4 (2665 ± 160.2 to 28060 ± 808 pg/ml) and LTC4/
D4 (1152 ± 159 to 8645 ± 771.8 pg/ml) as compared to
the control groups. The rats treated with montelukast
displayed significantly reduced levels of LTC4/D4 (8645
± 771.8 to 2331 ± 912.4), as shown in Fig. 2; however,
pre-treatment with montelukast did not significantly affect
LTB4 production (data not shown).
Effect of montelukast on alveolar macrophage
phagocytosis
Macrophages from sensitized rats showed
increased phagocytosis eight hours after incubation
with lamb red blood cells, as compared to the control
group (255 ± 45.5 to 826.5 ± 91.6), and this increase
Fig. 1. Effect of montelukast on bronchoalveolar lavage cells.
Rats were immunized with OVA and challenged with OVA
aerosol. Montelukast was given i.p. 30 min. before aerosol
challenge. Bronchoalveolar lavage was performed 24 h after
challenge. Eosinophils and neutrophils were counted in a
cytocentrifuge preparation of bronchoalveolar lavage cells
stained with hematoxylin and eosin. The results represent the
mean ± S.E.M. of 6 animals per group. * P< 0.01 compared with
the control group, and # P< 0.05 compared with the non-treated
group.
Fig. 2. Cys-leukotriene production in lung tissue and effect of
Montelukast. Leukotriene production was measured using the
EIA kit. The results represent the mean ± S.E.M. of 6 animals
per group. * P< 0.01 compared with the control group, and
# P< 0.05 compared with the immunized group.
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persisted up to 24 h (255 ± 45.5 to 1709 ± 207.3) (Fig.
3A). The addition of cys-LTs resulted in an increased
rate of AM phagocytosis (149%) in the control group.
Immunized and challenged rats showed similar
phagocytosis indices when compared to control animals
stimulated with LTC4; however, the phagocytic capacity
of this experimental group did not increase in response
to stimulation with LTC4 (Fig. 3 B). Figure 3 C shows
Fig. 3. Phagocytosis assay of red blood cells opsonized with
IgG and evaluation of the phagocytic index. Resident
macrophages from immunized male Wistar rats were obtained
by ex vivo bronchoalveolar lavage. (A) shows that AMs from
sensitized rats demonstrated a significant increase in
phagocytosis via FcγR that persisted up to 24 h. (B) shows
that the addition of LTs increased the rate of phagocytosis,
and C shows that montelukast reduced the rate of AM
phagocytosis in the immunized group. The results represent
the mean ± S.E.M. of 6 animals per group. * P< 0.01 compared
with the control group, and # P< 0.05 compared with the
immunized group.
Fig. 4. (A) - Killing of K. pneumoniae by alveolar macrophages
and effect of montelukast. AMs were infected with
K. pneumoniae in vitro. After 3 hours, the macrophages were
removed by scraping, and aliquots were cultured to determine
the number of viable organisms by quantitative culture. (B)
shows the production of nitric oxide in culture supernatants
and the effect of montelukast. Nitric oxide production
was measured using the Griess colorimetric reaction following
the addition of sheep red blood cells (SRBCs) to AMs.
The results represent the mean ± S.E.M. of 6 animals per group.
* P< 0.05 compared with the control group, and # P< 0.05
compared with the immunized group.
that treatment with the cys-LTS antagonist reversed
the increased phagocytic index of alveolar macrophages
from immunized and challenged rats.
Effect of montelukast on macrophage killing and
nitric oxide generation
An increased rate of killing of internalized bacteria
was observed in AMs from sensitized rats (128 ± 2 to 33
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± 1.5 CFU x 104); however, AMs collected from sensitized
rats treated with a cys-LTS antagonist prior to antigen
challenge showed a reduced killing capacity (33 ± 1.5 to
103 ± 2.6 CFU x 104) (Fig. 4A).
The culture supernatant of macrophages from rats
sensitized contained higher levels of nitric oxide compared
to the control group (38.3 ± 5.2 to 81.9 ± 3 μmol NO2-).
However, the pre-treatment of immunized rats with
montelukast significantly reduced nitric oxide production
in the culture supernatants of AMs (81.9 ± 3 to 50 ± 5.8
μmol NO2-) (Fig. 4B).
Discussion
The present study established the importance of LTs
in the phagocytic and microbicidal activities of
macrophages from rat lungs undergoing allergic lung
inflammation. Moreover, we demonstrated the relevance
of endogenous and exogenous LTs in the in vitro activities
of alveolar macrophages and in the production of NO.
It has been well-established that LTB4 and Cys-LTs
are potent chemotactic factors involved in the recruitment
of cells at the inflammation site [23-25]. Cuzzocrea et al.
[26] showed decrease in neutrophil infiltration due to the
absence of 5-LO, and aerosolized cys-LTs elicit the
recruitment of eosinophils to the lung in guinea pigs, which
is blocked by Cys-LT1 antagonists [27, 28]. Consistent
with these data, our results demonstrated that in rats
treated with montelukast, there was a direct relationship
between leukocyte infiltration and Cys-LT production in
the lung tissue. Moreover, in rats pretreated with
montelukast, we also observed a reduced infiltration of
polymorphonuclear cells in the lung tissue, as evaluated
by histological examination (data not shown). The reduced
levels of LTC4 observed in the lung tissue of immunized
and challenged rats pretreated with the cys-LT antagonist
corroborate the results of our previous studies [11] and
can be explained by the reduced infiltration of
inflammatory cells in lung tissue following montelukast
treatment. Polymorphonuclear cells produce leukotrienes,
and the reduced cell infiltration after treatment with
montelukast could explain the decrease in leukotrienes
levels observed in the lung tissue.
It has been demonstrated in different infection
models that LTs increase the effector functions of
phagocyte, including phagocytosis, microbicidal activity,
the generation of reactive oxygen and nitrogen species,
and secretion of proinflammatory cytokines [1]. It has
also been established that LTs increase the phagocytosis
of IgG- and complement-opsonized targets as well as
microbicidal activity and amplify a number of relevant
signal transduction events [2, 29].
We demonstrated that macrophages from rats
sensitized and challenged with ovalbumin aerosol had an
increased capacity to phagocytosis IgG- and complement-
opsonized targets and to kill K. pneumoniae, and
treatment of the rats with montelukast abolished these
events. The main finding of the present study is that
treatment with montelukast decreased the production of
LTC4 by lung tissue. We propose that this reduction could
be related to the functional impairment in in vitro
phagocytosis and microbicidal activity observed in
macrophages from immunized and challenged rats.
The ligation of Fc receptors not only results in
phagocytosis but also the synthesis and release of O2-
and H2O2, which are powerful oxidants that either alone
or in concert with leukocyte enzymes efficiently kill
pathogens [30]. In fact, the superoxide anion (O2-) and
nitric oxide have been identified as critical for the control
of leishmania infections [31].
Although the studies cited above have provided a
vast amount of information about the role of NO in
bacterial pathogenesis, caution is needed in extrapolating
these findings to human cells, because iNOS expression
and the production of NO by AMs differ dramatically
among species [32]. The ability of AMs to produce NO
and to kill bacteria has been alluded to in a number of
clinical studies [33-36]; however, the majority of NO
bacterial pathogenesis studies have relied on information
obtained using rodent models, reinforcing the importance
of animal models [37-39]. In the present study, AMs from
immunized and challenged rats demonstrated a significant
increase in production NO in response to a stimulus, and
treatment with montelukast abolished this event. The
addition of LTC4 on AMs culture stimulated a significant
increase in NO production and K. pneumoniae killing.
In fact, the relationship between nitric oxide (NO) and
cysteinyl LTs has been demonstrated in previous studies.
Yang et al. [40] have shown that sodium nitroprusside, a
nitric oxide donor, down-regulates the mRNA expression
of LTC4 synthesis enzymes in hepatic ischemia/
reperfusion injury in rats via the NF-kappaB signaling
pathway. Our results are consistent with those of Ko and
Cho [41], who observed a reduction in the level of LTC4
after administration of L-NAME (an inhibitor of nitric
oxide synthesis). However, the regulatory mechanism of
these mediators remains unknown.
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Taken together, these results suggest that LTs
produced during allergic lung inflammation can potentiate
the capacity of alveolar macrophages to phagocytose and
eliminate K. pneumoniae via FcγR. These results raise
the possibility that asthmatics might be more resistant to
infections caused by airway pathogens, and thus,
treatment with LTs antagonists could abolish this protective
effect of allergy.
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